Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease
Clinical and Experimental Nephrology · 2026
DOI: 10.1007/s10157-026-02897-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Nephrology, 2026. Verfasst von Chie Saito und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: Cilostazol, Glomerular Filtration Rate, Renal Insufficiency, Chronic, Renal Circulation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Promotion of Innovative R and D.
Abstract (Originalsprache)
Background
Cilostazol has antiplatelet and vasodilatory properties and may provide renoprotective and cardiovascular benefits; however, its effects in patients with advanced chronic kidney disease (CKD) remain unclear.
Methods
This prospective pilot study enrolled 12 patients with advanced CKD due to nephrosclerosis (7 men, 5 women; mean age 65.3 ± 11.0 years). Patients were randomly assigned to receive cilostazol 200 mg/day plus aspirin 100 mg/day (Group C, n = 6) or aspirin 100 mg/day alone (Group A, n = 6). Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin and para-aminohippuric acid clearance at baseline and after 1 year. Renal outcomes and complications were evaluated, followed by long-term observation until initiation of renal replacement therapy (RRT).
Results
Baseline GFR and RPF were comparable between groups. After 1 year, GFR increased in 4 of 6 patients in Group C but declined in all patients in Group A. Mean GFR decreased significantly in Group A but not in Group C. Although estimated GFR declined in both groups, the annual rate of decline was significantly slower in Group C than in Group A (− 2.72 vs. − 3.84 mL/min/1.73 m 2 /year). RPF and urinary protein levels showed no significant changes in either group. Over a mean follow-up of 6.7 years, RRT was initiated in 2 patients in Group C and 4 in Group A. Two cerebral infarctions occurred in Group A, whereas no cardiovascular events occurred in Group C.
Conclusion
Cilostazol may slow short-term renal function decline and offer long-term cardiovascular protection in patients with advanced CKD. Further studies are needed to determine its role in preventing long-term renal deterioration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Nephrology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. k-yamaga@md.tsukuba.ac.jp.
Förderung
- Strategic Promotion of Innovative R and D
Zitieren
APA
Saito, C., Mase, K., Ishibashi, S., Harada, T., Tsunoda, R., Usui, T., Simizu, T., Nagai, K., Ohkubo, R., Morito, N., Hagiwara, M., Kai, H., Usui, J., & Yamagata, K. (2026). Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-026-02897-8
Vancouver
Saito C, Mase K, Ishibashi S, Harada T, Tsunoda R, Usui T, et al. Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease. Clinical and Experimental Nephrology. 2026. doi:10.1007/s10157-026-02897-8
BibTeX
@article{Saito2026,
author = {Saito, Chie and Mase, Kaori and Ishibashi, Shun and Harada, Takuya and Tsunoda, Ryoya and Usui, Toshiaki and Simizu, Tatsuya and Nagai, Kei and Ohkubo, Reiko and Morito, Naoki and Hagiwara, Masahiro and Kai, Hirayasu and Usui, Joichi and Yamagata, Kunihiro},
title = {Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease},
journal = {Clinical and Experimental Nephrology},
year = {2026},
doi = {10.1007/s10157-026-02897-8}
}
EUVIMED